Advanced Clinical Evaluation and Clinical Investigation of Medical Devices (ISO 14155:2026 and ISO 18969)
Live online

Advanced Clinical Evaluation and Clinical Investigation of Medical Devices (ISO 14155:2026 and ISO 18969)

Clinical investigation through the assessor's lens: ISO 14155:2026, ISO 18969, MDR, FDA, Anvisa and Latin America. A 24-hour live course.

Duration
24 hours
Format
Live online
Certification
HSC Global

About the course

A 24-hour live course that prepares professionals to defend a medical device clinical investigation before four assessors at once: a notified body, the FDA, Anvisa and Latin American agencies. It approaches ISO 14155:2026 through the assessor's lens, with a "what changed from 2020 to 2026" overview, and connects the investigation to the ISO 18969 clinical evaluation process.

A continuous integrated case (NOVA-LAA, a fictitious class III left atrial appendage occluder) runs through all 8 modules, from the evidence gap to PMCF. The exercises involve critical analysis, gap identification and decision-making on fictitious excerpts.

Assessment and certificate

Pass mark of 70% in the 20-question final assessment (online, up to 7 days after the last session) and participation in the integrated case.

What you will learn

Module 01 / 3 hFundamentals, ethics and investigation planning

Scope, definitions and relationship with ISO 14971, ICH E6(R3) and the Declaration of Helsinki; GCP principles and ethical considerations (ethics committee, consent, vulnerable populations, public registration); planning: risk assessment, design justification, content of the CIP (Annex A), the IB (Annex B) and the CRF (Annex C), monitoring and site selection. Exercise: planning compliance.

Module 02 / 3 hConduct, safety, close-out and responsibilities

Study start-up, essential documents, device traceability, source data and deviations; AE, SAE, ADE, SADE, USADE and device deficiency; sponsor and investigator responsibilities; suspension, termination, close-out and the investigation report. Exercise: monitoring visit.

Module 03 / 3 hWhat changed from 2020 to 2026 and what assessors now expect

Publication of ISO 14155:2026 and its effect on ongoing studies; three risk categories and benefit-risk evaluation; DMC and CEC; Annex K (estimands and intercurrent events); consent for samples and data, implant card, new IB items, risk-based monitoring and Annex ZA. Exercise: compliant in 2020, compliant in 2026?

Module 04 / 3 hWorkshop: action plan to bring a product into line with ISO 14155:2026

Prioritisation criteria (participant safety, data integrity and regulatory acceptance); types of response and approvals by jurisdiction; gap analysis and action plan for the NOVA-LAA case, defended before the instructor acting as a notified body.

Module 05 / 3 hClinical investigation or literature? The decision under ISO 18969

Clinical evaluation as a process and the ISO 18969 ↔ ISO 14155 interface; evidence gaps, claims and state of the art; the literature route (equivalence, post-market data and RWE); when a clinical investigation is mandatory in the EU, the US and Brazil. Exercise: decision committee.

Module 06 / 3 hEuropean Union (MDR) and FDA

MDR: Arts. 62 to 80 and Annex XV, substantial modification and notifications; FDA: significant versus non-significant risk, IDE, EFS, Q-Submission, IRB, BIMO inspection, data from outside the US (812.28) and RWE. Exercise: significant risk or not, and choice of pathway.

Module 07 / 3 hAnvisa, CEP/CONEP and Latin America; multinational studies

Anvisa (DICD and DEEC, approval, amendments, notifications, importation); the CEP/CONEP system (Law 14.874/2024, CNS Resolution 466/2012, Plataforma Brasil, LGPD); ANMAT, COFEPRIS, INVIMA and ISP side by side; submission sequencing and the critical path of a multinational study.

Module 08 / 3 hThe other side of the table: how each agency assesses + integrating case

Closing the cycle through ISO 18969 (investigation report, CER, PMCF, PSUR/SSCP); how NBs, the FDA and Anvisa review; the most common findings in GCP audits and inspections; final integrated case before panels (NB, FDA, Anvisa and CEP).

Learning objective

By the end, participants can read an investigation plan, a report or a clinical evaluation and state, citing clause and article, what a notified body, the FDA, Anvisa or a CEP will question.

Who this course is for

Regulatory Affairs, Clinical Affairs, Quality and Medical Affairs at manufacturers; CROs and monitors; investigators; CEP members. Prerequisites: basic knowledge of Good Clinical Practice and risk management (ISO 14971). ISO 14155 is taught from the ground up; those who already master the 2020 edition use the first modules as a refresher.